The comparatively small size of the Canadian funds also constrains fund managers' capacity to invest in infrastructure and hire a larger bench of seasoned executives to support and advise the companies in their portfolio. [...] For example, the Health and Biosciences Economic Strategy Table convened by the Government of Canada established the following vision for the sector: “By 2025, Canada will double the size of the health and biosciences sector and become a top-three global hub by leveraging and advancing innovative technologies; attracting and retaining capital, skills and talent; and ensuring a vibrant ecosystem th. [...] In particular, they set targets to double health and biosciences exports to $26B, double the number of health and bioscience firms to 1,800, and double the number of health and bioscience high-growth firms to 80. [...] The TTOs don't have the “A lot of the biotech innovation capital or the expertise to set up is coming out of the companies to raise private universities , but we need a capital. [...] In turn, these trends could boost the number of life sciences startups and further justify the need to increase the amount of seed capital available in Canada and expand and diversify the number of seed investors.
- Pages
- 82
- Published in
- Canada
